∞ TICKERS
← Back to Screener

Myriad Genetics Inc (MYGN)

Price$4.28
Value ScoreC
Growth ScoreC
Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-58.39%
Price vs S&P 500 (4W)-22.26%
VGM Score48.69
Market Capitalization$382.04M

All Metrics

P/CF (Annual)212.25x
Book Value / Share (Quarterly)$3.57
P/TBV (Annual)2.67x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)6.72%
Cash Flow / Share (Quarterly)$-0.25
Price vs S&P 500 (YTD)-46.38%
Gross Margin (TTM)69.96%
Net Profit Margin (TTM)-48.24%
EPS (TTM)$-4.32
10-Day Avg Trading Volume2.01M
EPS Excl Extra (TTM)$-4.32
Revenue Growth (5Y)22.43%
EPS (Annual)$-3.95
ROI (Annual)-74.99%
Gross Margin (Annual)69.93%
Net Profit Margin (5Y Avg)-23.00%
Cash / Share (Quarterly)$1.32
Revenue Growth QoQ (YoY)2.30%
ROA (Last FY)-51.78%
Revenue Growth TTM (YoY)-0.28%
EBITD / Share (TTM)$-3.62
ROE (5Y Avg)-33.33%
Operating Margin (TTM)-46.91%
Cash Flow / Share (Annual)$-0.27
P/B Ratio1.13x
P/B Ratio (Quarterly)1.25x
Net Income / Employee (Annual)$-135,500
EV / Revenue (TTM)0.46x
Net Interest Coverage (TTM)-44.41x
ROA (TTM)-57.42%
EV / EBITDA (TTM)42.95x
EPS Incl Extra (Annual)$-3.95
Current Ratio (Annual)2.49x
Quick Ratio (Quarterly)1.91x
3-Month Avg Trading Volume1.72M
52-Week Price Return-4.57%
Revenue / Employee (TTM)$307,000
Tangible BV / Share (Quarterly)$2.03
P/S Ratio (Annual)0.46x
Asset Turnover (Annual)1.17x
52-Week High$8.59
Operating Margin (5Y Avg)-24.72%
EPS Excl Extra (Annual)$-3.95
CapEx CAGR (5Y)21.85%
Tangible BV CAGR (5Y)-6.76%
26-Week Price Return-42.46%
Quick Ratio (Annual)1.98x
13-Week Price Return-18.31%
Total Debt / Equity (Annual)0.33x
Current Ratio (Quarterly)2.40x
Enterprise Value$377.94M
Revenue / Share Growth (5Y)17.37%
Asset Turnover (TTM)1.19x
Book Value / Share Growth (5Y)-19.56%
Revenue / Employee (Annual)$305,400
Inventory Turnover (Annual)8.53x
Pretax Margin (Annual)-47.92%
Cash / Share (Annual)$1.60
3-Month Return Std Dev71.05%
Gross Margin (5Y Avg)70.01%
Net Income / Employee (TTM)$-148,100
ROE (Last FY)-99.43%
Net Interest Coverage (Annual)-33.47x
EPS Basic Excl Extra (Annual)$-3.95
P/FCF (TTM)19.59x
Receivables Turnover (TTM)6.79x
Total Debt / Equity (Quarterly)0.36x
EPS Incl Extra (TTM)$-4.32
Receivables Turnover (Annual)6.97x
ROI (TTM)-84.84%
P/S Ratio (TTM)0.46x
Pretax Margin (5Y Avg)-25.29%
Revenue / Share (Annual)$8.90
Tangible BV / Share (Annual)$2.30
Forward P/E43.71x
Price vs S&P 500 (52W)-32.77%
Year-to-Date Return-35.45%
5-Day Price Return3.93%
EPS Normalized (Annual)$-3.95
ROA (5Y Avg)-19.71%
Net Profit Margin (Annual)-44.38%
Month-to-Date Return-16.42%
Cash Flow / Share (TTM)$-2.62
EBITD / Share (Annual)$-3.60
Operating Margin (Annual)-46.96%
LT Debt / Equity (Annual)0.33x
P/CF (TTM)159.18x
ROI (5Y Avg)-27.93%
LT Debt / Equity (Quarterly)0.36x
EPS Basic Excl Extra (TTM)$-4.32
P/TBV (Quarterly)2.19x
P/B Ratio (Annual)1.56x
Inventory Turnover (TTM)8.86x
Pretax Margin (TTM)-48.23%
Book Value / Share (Annual)$3.94
Price vs S&P 500 (13W)-28.06%
Beta1.73x
P/FCF (Annual)1910.21x
Revenue / Share (TTM)$8.85
ROE (TTM)-109.09%
52-Week Low$3.53
vGradeC
gGradeC
mGradeD
vgmGradeC
Show chart for

Earnings Surprise History

Q1 26-0.09est. -0.07

Analyst Recommendations

Feb 2026
Mar 2026
Apr 2026
May 2026
2.67
2.67
2.67
2.59

About

Myriad Genetics develops and commercializes molecular diagnostic tests that assess disease risk and guide treatment decisions across medical specialties. The company's portfolio includes BRACAnalysis CDx, GeneSight, MyChoice CDx, Prolaris, and other proprietary tests used to support earlier detection and precision treatment. Revenue is primarily generated in the United States with international operations.